0001209191-18-002547.txt : 20180105 0001209191-18-002547.hdr.sgml : 20180105 20180105183024 ACCESSION NUMBER: 0001209191-18-002547 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180104 FILED AS OF DATE: 20180105 DATE AS OF CHANGE: 20180105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yurasov Sergey CENTRAL INDEX KEY: 0001686295 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36561 FILM NUMBER: 18514484 MAIL ADDRESS: STREET 1: C/O IMMUNE DESIGN CORP. STREET 2: 1616 EASTLAKE AVE. E., SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immune Design Corp. CENTRAL INDEX KEY: 0001437786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262007174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVE. E STREET 2: SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (206) 682-0645 MAIL ADDRESS: STREET 1: 1616 EASTLAKE AVE. E STREET 2: SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: VACCSYS INC DATE OF NAME CHANGE: 20080617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-04 0 0001437786 Immune Design Corp. IMDZ 0001686295 Yurasov Sergey C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE WA 98102 0 1 0 0 Sr. VP, Clinic. Devel. & CMO Common Stock 2018-01-04 4 A 0 22000 0.00 A 28000 D Common Stock 2018-01-04 4 S 0 675 4.1725 D 27325 D Stock Option (right to buy) 4.05 2018-01-04 4 A 0 110000 0.00 A 2028-01-04 Common Stock 110000 110000 D Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date. One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. /s/ Stephen R. Brady, Attorney-In-Fact 2018-01-05